GB Sciences 

Operating across North America and Europe, GB Sciences, Inc. is dedicated to the research and development of plant-based pharmaceuticals. The company specializes in crafting cannabinoid-inspired medications and complex therapeutic formulations intended for the prescription drug market. Its extensive intellectual property portfolio addresses a variety of medical conditions, with programs currently in pre-clinical animal stages. These include initiatives for Parkinson's disease, neuropathic and chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular ailments. Formed in 2001 and headquartered in Las Vegas, Nevada, the company was formerly known as Growblox Sciences, Inc. before rebranding in October 2016.